NASDAQ:INKT MiNK Therapeutics (INKT) Stock Price, News & Analysis $11.26 +0.07 (+0.58%) As of 12:27 PM Eastern This is a fair market value price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock About MiNK Therapeutics Stock (NASDAQ:INKT) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get MiNK Therapeutics alerts:Sign Up Key Stats Today's Range$11.00▼$11.2450-Day Range$8.56▼$14.2152-Week Range$6.34▼$76.00Volume2,314 shsAverage Volume217,026 shsMarket Capitalization$56.05 millionP/E RatioN/ADividend YieldN/APrice Target$35.00Consensus RatingHold Company Overview MiNK Therapeutics, Inc. is a clinical-stage biotechnology company developing exosome-based immunotherapies for the treatment of solid tumors. The company’s proprietary platform isolates and engineers naturally occurring extracellular vesicles, or exosomes, to deliver therapeutic payloads—such as mRNA, proteins and modulatory factors—directly into the tumor microenvironment. By leveraging the innate cell‐to‐cell communication properties of exosomes, MiNK aims to reprogram immune cells and overcome immune suppression within solid tumors. MiNK’s preclinical pipeline features multiple lead candidates designed to repolarize tumor‐associated macrophages and boost T cell–mediated tumor clearance. The company has established scalable, GMP‐compatible manufacturing processes to produce engineered exosomes at clinically relevant volumes. Research efforts focus on optimizing biodistribution, payload loading efficiency and safety profiles in animal models, with the goal of advancing IND‐enabling studies for first‐in‐human trials. Headquartered in Cambridge, Massachusetts, MiNK collaborates with academic institutions and contract development organizations across North America and Europe to accelerate its research and development programs. The company’s integrated operations encompass discovery, preclinical testing and process development, supported by a team of experts in exosome biology, translational immunology and biomanufacturing. Through these partnerships and internal capabilities, MiNK aims to bring novel, precision immunotherapies to patients with high‐unmet‐need solid tumors.AI Generated. May Contain Errors. Read More MiNK Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks49th Percentile Overall ScoreINKT MarketRank™: MiNK Therapeutics scored higher than 49% of companies evaluated by MarketBeat, and ranked 332nd out of 860 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.6 / 5Analyst RatingHold Consensus RatingMiNK Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.40, and is based on 1 strong buy rating, 1 buy rating, 2 hold ratings, and 1 sell rating.Upside PotentialMiNK Therapeutics has a consensus price target of $35.00, representing about 210.1% upside from its current price of $11.29.Amount of Analyst CoverageMiNK Therapeutics has only been the subject of 2 research reports in the past 90 days.Read more about MiNK Therapeutics' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for MiNK Therapeutics are expected to decrease in the coming year, from ($3.27) to ($3.45) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of MiNK Therapeutics is -3.80, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of MiNK Therapeutics is -3.80, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Read more about MiNK Therapeutics' valuation and earnings. Short Interest5.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted2.51% of the float of MiNK Therapeutics has been sold short.Short Interest Ratio / Days to CoverMiNK Therapeutics has a short interest ratio ("days to cover") of 1.88, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in MiNK Therapeutics has recently decreased by 30.64%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldMiNK Therapeutics does not currently pay a dividend.Dividend GrowthMiNK Therapeutics does not have a long track record of dividend growth. News and Social Media0.6 / 5News SentimentN/A News Coverage This WeekMarketBeat has tracked 1 news article for MiNK Therapeutics this week, compared to 2 articles on an average week.MarketBeat Follows2 people have added MiNK Therapeutics to their MarketBeat watchlist in the last 30 days. Company Ownership1.5 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, MiNK Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $27,481.00 in company stock.Percentage Held by Insiders22.48% of the stock of MiNK Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions2.87% of the stock of MiNK Therapeutics is held by institutions.Read more about MiNK Therapeutics' insider trading history. Receive INKT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for MiNK Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. INKT Stock News HeadlinesMiNK Therapeutics, Inc. (NASDAQ:INKT) Receives $35.00 Consensus PT from AnalystsMay 5 at 4:10 AM | americanbankingnews.comMiNK Therapeutics Reports Phase II Data on Immune Reprogramming and Durable Survival in PD-1 Refractory Gastroesophageal CancerApril 18, 2026 | markets.businessinsider.comElon’s Biggest Launch Ever: 15x Bigger Than SpaceXThe Man Who Called Nvidia Before It Soared 1,000% Issues New Elon Musk BUY Alert Luke Lango was ranked America's #1 stock picker in 2020. He was mentored by two hedge fund billionaires from the Soros network and trained at Caltech. His readers have had the chance to see gains as high as AMD +8,500%... Nvidia +5,000%... Tesla +3,500%... Palantir +1,000%... and Apple +890%.May 8 at 1:00 AM | InvestorPlace (Ad)MiNK Therapeutics and Memorial Sloan Kettering to Present Phase II Study of agenT-797 Combination in PD-1 Refractory Gastroesophageal Cancer at AACR 2026April 3, 2026 | globenewswire.comMiNK Therapeutics to Present New Data at ASGCT 2026 Highlighting Context-Dependent Activity of iNKT Cell TherapyApril 2, 2026 | markets.businessinsider.comMiNK Therapeutics' AgenT-797 Abstract Accepted for Presentation at ASGCT Annual Meeting 2026April 2, 2026 | quiverquant.comQMiNK Therapeutics Announces Abstract Acceptance for Presentation at the American Thoracic Society (ATS) 2026 International ConferenceApril 1, 2026 | globenewswire.comMiNK outlines initial ARDS Phase II data in H2 2026 while extending runway through 2026March 31, 2026 | seekingalpha.comSee More Headlines INKT Stock Analysis - Frequently Asked Questions How have INKT shares performed this year? MiNK Therapeutics' stock was trading at $11.15 at the beginning of the year. Since then, INKT stock has increased by 1.2% and is now trading at $11.2850. How were MiNK Therapeutics' earnings last quarter? MiNK Therapeutics, Inc. (NASDAQ:INKT) announced its quarterly earnings results on Tuesday, March, 31st. The company reported ($0.54) EPS for the quarter, beating the consensus estimate of ($0.68) by $0.14. Read the conference call transcript. When did MiNK Therapeutics' stock split? Shares of MiNK Therapeutics reverse split on the morning of Tuesday, January 28th 2025.The 1-10 reverse split was announced on Tuesday, January 21st 2025. The number of shares owned by shareholders was adjusted after the market closes on Monday, January 27th 2025. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split. When did MiNK Therapeutics IPO? MiNK Therapeutics (INKT) raised $43 million in an initial public offering on Thursday, October 14th 2021. The company issued 3,333,334 shares at a price of $12.00-$14.00 per share. How do I buy shares of MiNK Therapeutics? Shares of INKT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of MiNK Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that MiNK Therapeutics investors own include Agenus (AGEN), HubSpot (HUBS), Meta Platforms (META), NVIDIA (NVDA), Tesla (TSLA) and Bank of America (BAC). Company Calendar Last Earnings3/31/2026Today5/08/2026Next Earnings (Estimated)5/13/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Red Zone (9m+) 1-Year History May 25 Aug 25 Nov 25 Feb 26 May 26 INKT's financial health is in the Red zone, according to TradeSmith. INKT has been in this zone for over 9 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:INKT CIK1840229 Webwww.minktherapeutics.com Phone212-994-8250FaxN/AEmployees30Year Founded2017Price Target and Rating Average Price Target for MiNK Therapeutics$35.00 High Price Target$35.00 Low Price Target$35.00 Potential Upside/Downside+210.1%Consensus RatingHold Rating Score (0-4)2.40 Research Coverage5 Analysts Profitability EPS (Trailing Twelve Months)($2.97) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$12.49 million Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on Assets-139.00% Debt Debt-to-Equity RatioN/A Current Ratio1.06 Quick Ratio1.06 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value($3.03) per share Price / Book-3.72Miscellaneous Outstanding Shares4,980,000Free Float3,862,000Market Cap$56.20 million OptionableNo Data Beta0.47 Social Links (Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.Get This Free Report This page (NASDAQ:INKT) was last updated on 5/8/2026 by MarketBeat.com Staff. From Our PartnersYour book attachedYour Download Link (Expiring) If you still haven't downloaded the free Simple Options Trading For Beginners...Profits Run | SponsoredIran's New Leader Just Said Something That Should Terrify Every AmericanIran's Supreme Leader has declared the Strait of Hormuz closed as leverage against the U.S. - and with 40% of ...American Alternative | SponsoredBefore you buy SpaceX shares, consider this alternative approachSpaceX has confidentially filed for an IPO with the SEC, targeting a June 2026 listing at a valuation exceedin...Weiss Ratings | SponsoredOne executive order. The biggest wealth transfer of your lifetime.On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredSpaceX eyes a 1.75 trillion valuation - here's what to knowElon Musk's team has quietly filed confidential paperwork with the SEC for what Bloomberg estimates could be a...Brownstone Research | SponsoredThe Death of the Nasdaq?The Death of the Nasdaq? Wall Street legend Marc Chaikin's award-winning system turned bearish on software ...Chaikin Analytics | Sponsored"Computers are about to become obsolete" - George Gilder. Here’s why.George Gilder predicted the iPhone 16 years early, called Netflix a decade before it dominated streaming, and ...Eagle Publishing | SponsoredSatellite Images Spot Potential $10 Trillion Discovery'Dark Energy': Elon Musk's Next Potential $10 Trillion Move A highly secure site in West Texas now houses a...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding MiNK Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share MiNK Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
